List view / Grid view
29 January 2015 | By TxCell
Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease...
27 January 2015 | By TxCell
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces the receipt of EUR 1.7 million from Bpifrance...
8 January 2015 | By Advanced Accelerator Applications S.A.
Advanced Accelerator Applications S.A. announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada...
8 January 2015 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
6 January 2015 | By TxCell
TxCell SA (FR0010127662 – TXCL) announces that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis...
12 November 2014 | By Enterome
Collaboration to generate novel diagnostic products to support personalized therapies for microbiome-related diseases...
28 October 2014 | By TxCell
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease...
25 September 2014 | By TXCELL
TxCell reports its financial results for the first half of 2014...
